Cellectar Biosciences
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Campus Dr Ste 207, Florham Park, New...Phone Number
(608) 441-8120Website
www.cellectar.comRevenue
-Stock Symbol
CLRBIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.Explore more
Cellectar Biosciences Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellectar Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Cellectar Biosciences
Check out if Cellectar Biosciences is spiking on competitors!
Earning: See what the market has to say on Cellectar Biosciences recently announced quarterly report
Click to see if Cellectar Biosciences had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Cellectar Biosciences has new funding data
Product Launch: Get notified when Cellectar Biosciences launches new products
Check if Cellectar Biosciences has recently received funding, and reach out quickly before it becomes old news!
Cellectar Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Cellectar Biosciences
Compare insights from companies similar to Cellectar Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cellectar Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cellectar Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cellectar Biosciences.
Cellectar Biosciences financials insights
Gather financial insights about Cellectar Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Stock Offering
$9.2M
2017
Stock Offering
$7.8M
2018
Stock Offering
$16.6M
2019
Stock Offering
$10M
2020
Debt
$150K
2023
Share Placement
$102.9M
2025
Stock/Share Issuance
$2.5M
Cellectar Biosciences Tech Stack
A closer look at the technologies used by Cellectar Biosciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Spending/Investment, Finance, Financial Operations
Cellectar Biosciences News & Media
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call May 14, 2026 8:30 AM EDTCompany ParticipantsJames Caruso - President, CEO & DirectorChad Kolean...Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time.Cellectar Biosciences Raises ~$35 Million in Registered Direct and Private Placement
Cellectar Biosciences entered multiple agreements to complete a capital raise of approximately $35 million through a registered direct offering and concurrent private placement. The financing includes common stock, pre-funded warrants, and milestone-based Tranche A, B, and C warrants, with proceeds…
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellectar Biosciences
Sign Up For FreeTo access detailed company insights
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study fo... Read More
